- Home
- ANEB vs CALC Comparison
ANEB vs CALC Comparison
Compare ANEB & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- CALC
- Stock Information
- Founded
- ANEB 2020
- CALC 2011
- Country
- ANEB United States
- CALC United States
- Employees
- ANEB N/A
- CALC N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- CALC Health Care
- Exchange
- ANEB Nasdaq
- CALC Nasdaq
- Market Cap
- ANEB 39.0M
- CALC 22.9M
- IPO Year
- ANEB 2021
- CALC N/A
- Fundamental
- Price
- ANEB $1.74
- CALC $1.64
- Analyst Decision
- ANEB Strong Buy
- CALC Strong Buy
- Analyst Count
- ANEB 2
- CALC 3
- Target Price
- ANEB $5.50
- CALC $16.33
- AVG Volume (30 Days)
- ANEB 20.6K
- CALC 28.9K
- Earning Date
- ANEB 05-13-2025
- CALC 08-11-2025
- Dividend Yield
- ANEB N/A
- CALC N/A
- EPS Growth
- ANEB N/A
- CALC N/A
- EPS
- ANEB N/A
- CALC N/A
- Revenue
- ANEB N/A
- CALC N/A
- Revenue This Year
- ANEB N/A
- CALC N/A
- Revenue Next Year
- ANEB N/A
- CALC N/A
- P/E Ratio
- ANEB N/A
- CALC N/A
- Revenue Growth
- ANEB N/A
- CALC N/A
- 52 Week Low
- ANEB $0.80
- CALC $1.42
- 52 Week High
- ANEB $3.08
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- ANEB 66.67
- CALC 49.89
- Support Level
- ANEB $1.57
- CALC $1.59
- Resistance Level
- ANEB $2.00
- CALC $1.69
- Average True Range (ATR)
- ANEB 0.26
- CALC 0.15
- MACD
- ANEB 0.01
- CALC 0.01
- Stochastic Oscillator
- ANEB 37.23
- CALC 52.26
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.